Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.

Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.

Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.